BioSpace News Archive

ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced the completion of a human bioavailability study of CMIO-OLNZ, a 7-day matrix transdermal delivery system of olanzapine for the treatment of poly ADP ribose polymerase (PARP) inhibitor induced nausea and vomiting (PIINV) (the “Study”).

Submission Marks On-time Execution of Second NDA Submission for Tazemetostat in 2019

Seattle Genetics, Inc. will host a conference call and webcast on Thursday, December 19, 2019 to discuss the U.S. Food and Drug Administration approval of PADCEVTM.

First-in-Class Antibody-Drug Conjugate Directed Against Nectin-4, a Protein Highly Expressed in Urothelial Tumors

Monopar Therapeutics Inc. announced that it has priced an initial public offering of 1,111,112 shares of its common stock at $8.00 per share.

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) voted 11 - 0 in favor of the benefit-risk profile of tazemetostat as a treatment for patients with metastatic or locally advanced epithelioid sarcoma (ES) not eligible for curative surger

The National Resident Matching Program® (NRMP®) has released the results of the 2019 Pediatric Specialties Match (PSM) for appointment year 2020.

Rezolute, Inc.(“Rezolute” or “the Company”) (OTCQB:RZLT) today announced top-line results from its Phase 1 trial of AB101, an ultra-long acting basal insulin for potential use in patients with type 1 and type 2 diabetes.

Cambia Health Foundation is committed to partnering with visionary organizations to foster a person-focused, accessible, and economically sustainable health care system that empowers everyone to achieve optimum health.

Quantum Leap Healthcare Collaborative™ (QLHC), sponsor and manager of the I-SPY TRIALs for Breast Cancer, announced today an evaluation of two drugs developed by Regeneron in a new randomized, investigational treatment arm for the ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.